Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Mark L, Levitt"'
Autor:
Fernando Carvalho Neuenschwander, Ofra Barnett-Griness, Stefania Piconi, Yasmin Maor, Eduardo Sprinz, Nimer Assy, Oleg Khmelnitskiy, Nikita V. Lomakin, Boris Mikhailovich Goloshchekin, Ewelina Nahorecka, Adilson Joaquim Westheimer Calvacante, Anastasia Ivanova, Sergey Vladimirovich Zhuravel, Galina Yurevna Trufanova, Stefano Bonora, Amer Saffoury, Ami Mayo, Yury G. Shvarts, Giuliano Rizzardini, Rogerio Sobroza de Mello, Janaina Pilau, Alexey Klinov, Benjamin Valente-Acosta, Oleg Olegovich Burlaka, Natalia Bakhtina, Maskit Bar-Meir, Ivan Nikolaevich Shishimorov, Jose Oñate-Gutierrez, Cristian Iván García Rincón, Tatiana Ivanovna Martynenko, Ludhmila Abrahão Hajjar, Ana Carolina Nazare de Mendonca Procopio, Krzysztof Simon, Walter Gabriel Chaves Santiago, Adam Fronczak, Conrado Roberto Hoffmann Filho, Osama Hussein, Vladimir Aleksandrovich Martynov, Guido Chichino, Piotr Blewaska, Jacek Wroblewski, Sergio Saul Irizar Santana, Andres Felipe Ocampo Agudelo, Adam Barczyk, Rachael lask Gerlach, Eppie Campbell, Aida Bibliowicz, Reza Fathi, Patricia Anderson, Gilead Raday, Michal Klein, Clara Fehrmann, Gina Eagle, Vered Katz Ben-Yair, Mark L. Levitt
Publikováno v:
Microorganisms, Vol 12, Iss 9, p 1767 (2024)
Once a patient has been diagnosed with severe COVID-19 pneumonia, treatment options have limited effectiveness. Opaganib is an oral treatment under investigation being evaluated for treatment of hospitalized patients with severe COVID-19 pneumonia. A
Externí odkaz:
https://doaj.org/article/4abee192ba974c30b03ccb75515ad1f3
Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Pneumonia
Autor:
Fernando Carvalho Neuenschwander, Ofra Barnett-Griness, Stefania Piconi, Yasmin Maor, Eduardo Sprinz, Nimer Assy, Oleg Khmelnitskiy, Nikita Lomakin, Boris Mikhailovich Goloshchekin, Ewelina Nahorecka, Adilson Joaquim Westheimer Calvacante, Anastasia Ivanova, Sergey Vladimirovich Zhuravel, Galina Yurevna Trufanova, Stefano Bonora, Amer Saffoury, Ami Mayo, Yury Shvarts, Giuliano Rizzardini, Rogerio Sobroza de Mello, Janaina Pilau, Alexey Klinov, Benjamin Valente-Acosta, Oleg Olegovich Burlaka, Natalia Bakhtina, Maskit Bar-Meir, Ivan Nikolaevich Shishimorov, Jose Oñate-Gutierrez, Cristian Ivan Garcia Rincon, Tatiana Ivanovna Martynenko, Ludhmila Abrahão Hajjar, Ana Carolina Nazare de Mendonca Procopio, Krzystof Simon, Walter Gabriel Chaves Santiago, Adam Fronczak, Conrado Roberto Hoffmann Filho, Osama Hussein, Vladimir Aleksandrovich Martynov, Guido Chichino, Piotr Blewaska, Jacek Wroblewski, Sergio Saul Irizar Santana, Andres Felipe Ocampo Agudelo, Adam Barczyk, Rachael L. Gerlach, Eppie Campbell, Aida Bibliowicz, Reza Fathi, Patricia Anderson, Gilead Raday, Michal Klein, Clara Fehrmann, Gina Eagle, Vered Katz Ben-Yair, Mark L. Levitt
RationaleThere are few treatment options for severe COVID-19 pneumonia. Opaganib is an oral treatment under investigation.ObjectiveEvaluate opaganib treatment in hospitalized patients with severe COVID-19 pneumonia.MethodsA randomized, placebo-contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac5a8655eb260c38557cc88d09eaf63c
https://doi.org/10.1101/2022.06.12.22276088
https://doi.org/10.1101/2022.06.12.22276088
Autor:
Kevin L, Winthrop, Alan W, Skolnick, Adnan M, Rafiq, Scott H, Beegle, Julian, Suszanski, Guenther, Koehne, Ofra, Barnett-Griness, Aida, Bibliowicz, Reza, Fathi, Patricia, Anderson, Gilead, Raday, Gina, Eagle, Vered Katz, Ben-Yair, Harold S, Minkowitz, Mark L, Levitt, Michael S, Gordon
Publikováno v:
Open Forum Infectious Diseases. 9
Background Opaganib, an oral sphingosine kinase-2 inhibitor with antiviral and anti-inflammatory properties, was shown to inhibit severe acute respiratory syndrome coronavirus 2 replication in vitro. We thus considered that opaganib could be benefici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68f33875e2beb27da2f8d2f5e869c44f
https://doi.org/10.1093/ofid/ofac232
https://doi.org/10.1093/ofid/ofac232
Autor:
Charles D Smith, Lynn W Maines, Staci N Keller, Vered Katz Ben-Yair, Reza Fathi, Terry F Plasse, Mark L Levitt
Publikováno v:
Drug design, development and therapy. 16
The Covid-19 pandemic driven by the SARS-CoV-2 virus continues to exert extensive humanitarian and economic stress across the world. Although antivirals active against mild disease have been identified recently, new drugs to treat moderate and severe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51c5b4443d4e5c50df53f269f4800ede
https://pubmed.ncbi.nlm.nih.gov/35855741
https://pubmed.ncbi.nlm.nih.gov/35855741
Autor:
Scott Beegle, Alan W Skolnick, Mark L. Levitt, Michael S Gordon, Patricia Anderson, Harold S Minkowitz, Gina Eagle, Guenther Koehne, Gilead Raday, Kevin L. Winthrop, Adnan Rafiq, Reza Fathi, Aida Bibliowicz, Ofra Barnett-Griness, Vered Katz Ben-Yair, Julian Suszanski
BackgroundOpaganib, an oral sphingosine kinase-2 inhibitor with antiviral and anti-inflammatory properties, was shown to inhibit SARS-CoV-2 replication in vitro. We thus considered that opaganib could be beneficial for moderate to severe COVID-19 pne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11367e9baa18250ae680554587c233e6
https://doi.org/10.1101/2021.08.23.21262464
https://doi.org/10.1101/2021.08.23.21262464
Autor:
Yo Han Kim, Lewis R. Roberts, Jennifer L. Leiting, Nellie A. Campbell, Sarah A. Buhrow, Daniel R. O'Brien, Faizal Z. Asumda, Joel M. Reid, Mark L. Levitt, Mohamed A. Hassan, Michael J. Moore, Reza Fathi, Mark J. Truty, Vered Katz Ben-Yair, Xin Luo, Fabrice Lucien-Matteoni
Publikováno v:
Cancer Research. 80:3078-3078
Background: Upamostat is an orally available small molecule serine protease inhibitor that is a highly potent inhibitor of trypsin 1, trypsin 2 and trypsin 3 (PRSS1/2/3) as well as urokinase-type plasminogen activator (uPA) which are expressed in man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a139ab9752076ef46bd7f54998a08543
https://doi.org/10.1158/1538-7445.am2020-3078
https://doi.org/10.1158/1538-7445.am2020-3078
Autor:
Terry F. Plasse, Christine R. Schar, Jan K. Jensen, Emil Oldenburg, Mark L. Levitt, Eric M. Towler, Eva Louise Lange, Reza Fathi, Danielle T. Abramson
Publikováno v:
Cancer Research. 78:4200-4200
WX-UK1 (the active metabolite of upamostat) was originally developed as an inhibitor of the serine protease urokinase (uPA) with a Ki ~1 uM. To identify more sensitive targets, we performed a bioinformatic analysis of the ~200 human trypsin-like seri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5256e7552ed1508c737ab56577a42393
https://doi.org/10.1158/1538-7445.am2018-4200
https://doi.org/10.1158/1538-7445.am2018-4200
Autor:
Eva Louise Lange, Reza Fathi, Danielle T. Abramson, Mark L. Levitt, Jan K. Jensen, Terry F. Plasse, Christine R. Schar, Emil Oldenberg
Publikováno v:
Molecular Cancer Therapeutics. 17:B055-B055
WX-UK1, a multi-serine protease inhibitor, was believed to function primarily as a synthetic small-molecule inhibitor of urokinase (uPA). We now reveal that WX-UK1 is a potent and rather specific inhibitor of human trypsin-2 and human trypsin-3, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06c1757c2d7bf494d17b4f111721d091
https://doi.org/10.1158/1535-7163.targ-17-b055
https://doi.org/10.1158/1535-7163.targ-17-b055
Autor:
Raphael Pfeffer, Zvi Symon, Bernice Oberman, Baruch Brenner, Mark L. Levitt, Yulia Kundel, Thomas Tichler, Raphael Catane, Siegal Sadezki
Publikováno v:
Tumori Journal. 94:469-473
Aims and Background To analyze the efficacy and toxicity of adjuvant chemotherapy followed by whole abdominal irradiation in the treatment of resectable gastric cancer with positive lymph nodes. Methods and Study Design Between 1996 and 1999, 10 pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d52ad6c1ee68390cff4de4e2d5825bf
https://doi.org/10.1177/030089160809400405
https://doi.org/10.1177/030089160809400405
Autor:
Wilbur A. Franklin, Rodney J. Landreneau, Haifan Zhang, Patrick P. Koty, Samuel A. Yousem, Mark L. Levitt
Publikováno v:
Lung Cancer. 35:155-163
Forty-four specimens of non-malignant and malignant human lung tissue, taken from patients with non-small cell lung cancer (NSCLC), were examined for the expression of wild-type p53, mutant p53, and bcl-2 and the occurrence of programmed cell death (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5fc0bbb20f8dccea64b5202a32ee42f
https://doi.org/10.1016/s0169-5002(01)00411-1
https://doi.org/10.1016/s0169-5002(01)00411-1